Traws Pharma is developing proprietary targeted direct antiviral investigational product candidates for daily oral delivery, aiming to provide treatment or prophylaxis against seasonal or pandemic respiratory viral diseases.

Traws Pharma combines excellence in medicinal chemistry with the tools of AI and machine learning, to guide and accelerate the drug development process. We focus on creating new drugs capable of targeting affected tissues, that may potentially provide treatment options to a broader part of the disease population. A particular focus of the company’s design efforts is to overcome problems introduced when viruses become resistant to current therapies and new drugs are needed. Traws Pharma also aims to address the need for special therapies including long-acting treatments designed to prevent disease by blocking the initial infection.